Lower Incidence of Severe Damage to Target Organs in Mexican Patients With Systemic Sclerosis and Diffuse Skin Affection

Rojas-Serrano, Jorge; Codina-Velásquez, Helga; Medrano-Ramírez, Gabriel; Abraham Simón, J.; Vera-Lastra, Olga; Vázquez-Mellado, Janitzia

doi:10.1016/S2173-5743(08)70142-4

Article information

Objective

To determine the cumulative incidence of severe organ involvement in Mexican patients with systemic sclerosis (SS) and diffuse scleroderma at 3 years from the onset of SS symptoms, and to compare it with the cumulative incidence observed in a cohort of white patients with SS.

Patients and method

Patients with SS and diffuse scleroderma were evaluated within the first 2 years from the onset of SS symptoms and were included. An estimation of the cumulative incidence of severe involvement to the skin, kidney, heart, lungs, and gastrointestinal track at 3 years from the onset of SS symptoms was carried out. This cumulative incidence was compared with that of white SS patients with diffuse scleroderma, using the one sample test for a binomial proportion.

Results

Sixty-three patients were included. The cumulative incidence of severe involvement to the skin was 3.17% (2/63) (95% CI, 0.04–11); kidney involvement in 4.17% (3/63) (95% CI, 0.99–13.29); heart involvement in 1.6% (1/63) (95% CI, 0.04–8.5); lung involvement in 11.11% (7/63) (95% CI, 4.5–21.5); and gastrointestinal involvement in 4.7% (3/63) (95% CI, 0.99–13.3). Mexican patients had a lower incidence of severe skin involvement (P=.0001), kidney involvement (P=.03), and heart involvement (P=.03) compared to white SS patients with diffuse scleroderma.

Conclusions

The cumulative incidence of severe organ involvement in SS Mexican patients with diffuse scleroderma was determined. The incidence of severe skin, kidney, and heart involvement is lower than in white SS patients with diffuse scleroderma.

Key words:

Systemic sclerosis

Diffuse scleroderma

Ethnic differences in epidemiology

Clinical expression differences

Objetivo

Determinar la incidencia acumulada de daño grave en órganos diana en la esclerosis sistémica con afección cutánea difusa (ESD), en una cohorte de pacientes mexicanos a los 3 años desde el inicio de los síntomas de la enfermedad, y compararla con lo observado en una cohorte de pacientes blancos.

Pacientes y método

Se incluyó a los pacientes evaluados por primera vez en los primeros 2 años desde el inicio de los síntomas de la ESD. Se determinó la incidencia acumulada de daño grave en los siguientes órganos: piel, riñones, sistemas cardiovascular, pulmonar y gastrointestinal, y se comparó con lo observado en una cohorte donde el 94% de los pacientes son blancos, mediante la prueba de una muestra para una proporción binomial.

Resultados

Se encontró que 63 pacientes cumplían los criterios del estudio. La incidencia acumulada de daño grave en la piel fue del 3,17% (2/63) (intervalo de confianza [IC] del 95%, 0,04–11); daño renal del 4,17% (3/63) (IC del 95%, 0,99–13,29); daño cardiovascular del 1,6% (1/63) (IC del 95%, 0,04–8,5); daño pulmonar grave del 11,11% (7/63) (IC del 95%, 4,5–21,5), y daño gastrointestinal del 4,7% (3/63) (IC del 95%, 0,99–13,3). Al comparar los datos con los observados en pacientes blancos en el mismo período de evolución de la ESD, se encontró una menor incidencia de daño grave en la piel (p=0,0001), y daño renal (p=0,03) y cardiovascular (p=0,03).

Conclusiones

Se determinó la incidencia de daño grave en órganos diana en pacientes mexicanos con ESD a los 3 años desde el inicio de los síntomas. La incidencia de daño de piel, y daño renal y cardiovascular es menor que lo observado en pacientes de raza blanca.

Palabras clave:

Esclerosis sistémica

Esclerodermia difusa

Diferencias étnicas en epidemiología

Diferencias en la expresión clínica

Full text is only aviable in PDF

References

[1.]

T.A. Medsger Jr..

Systemic sclerosis (scleroderma): clinical aspects.

Artritis and allied conditions. A textbook of rheumatology, 14.a, pp. 1590-1624

[2.]

V.D. Steen, T.A. Medsger.

Severe organ involvement in systemic sclerosis with diffuse scleroderma.

Arthritis Rheum, 43 (2000), pp. 2437-2444

http://dx.doi.org/10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U | Medline

[3.]

T.J. Laing, B.W. Gillepie, M.B. Toth, M.D. Mayes, R.H. Gallavan, C.J. Burns, et al.

Racial differences in scleroderma among women in Michigan.

Arthritis Rheum, 40 (1997), pp. 734-742

http://dx.doi.org/10.1002/1529-0131(199704)40:4<734::AID-ART20>3.0.CO;2-3 | Medline

[4.]

J.D. Reveille, M. Fischbach, T. McNearney, A.W. Friedman, M.B. Aguilar, J. Lisse.

Systemic sclerosis in 3 US ethnic groups: a comparison of clinical sociodemographic, serologic, and immunogenic determinants.

Semin Arth Rheum, 30 (2001), pp. 332-346

[5.]

V.D. Steen, C. Conte, G.R. Owena, T.A. Medsger.

Severe restrictive lung disease in systemic sclerosis.

Arthritis Rheum, 37 (1994), pp. 1283-1289

Medline

[6.]

M. Kuwana, J. Kaburaki, F.C. Arnett, R.F. Howard, T.A. Medsger, T.M. Wright.

Influence of ethnic background on clinical and serological features in patients with systemic slcerodid and anti-DNA topoisomerase I antibody.

Arthritis Rheum, 42 (1999), pp. 465-474

http://dx.doi.org/10.1002/1529-0131(199904)42:3<465::AID-ANR11>3.0.CO;2-Y | Medline

[7.]

Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Preliminary criteria for the classification of systemic sclerosis (scleroderma).

Arthritis Rheum, 23 (1980), pp. 581-590

Medline

[8.]

E.C. LeRoy, C. Black, R. Fleischmajer, et al.

Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis.

J Rheumatol, 15 (1988), pp. 202-205

Medline

[9.]

V.D. Steen, T.A. Medsger Jr., G.P. Rodnan.

D-penicillamine therapy in progressive systemic sclerosis (scleroderma).

Ann Intern Med, 97 (1982), pp. 652-659

Medline

[10.]

P.J. Clements, D.E. Furst, W.-K. Wong, M. Mayes, B. White, F. Wigley, et al.

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double blind, randomized, controlled clinical trial.

Arthritis Rheum, 42 (1999), pp. 1194-1203

http://dx.doi.org/10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7 | Medline

[11.]

D.P. Taskhin, R. Elashoff, P.J. Clements, J. Goldin, M.D. Roth, D.E. Furst, et al.

Cyclophosphamide versus placebo in scleroderma lung disease.

N Engl J Med, 354 (2006), pp. 2655-2666

http://dx.doi.org/10.1056/NEJMoa055120 | Medline

[12.]

L.J. McNeilage, U. Younuchaiyud, S. Whittingham.

Racial differences in antinuclear antibody patterns and clincal manifestations of scleroderma.

Arthritis Rheum, 32 (1989), pp. 54-60

Medline